Target Organs and Levels of Evidence for TR-485

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Oxymetholone 434-07-1	10/30/1998	Gavage MR: 0, 3, 30, OR 150 MG/KG; FR: 0, 3, 30, OR 100 MG/KG	Battelle Columbus Laboratory

Type	Organ/Tissue (Lesion)
May Have Been Related	Skin: FIBROMA 0/51 5/50 2/49 2/50 COMBINED 0/51 7/50 2/49 2/50 Adrenal Gland Medulla: PHEOCHROMOCYTOMA 19/51 21/50 21/50 29/49 COMBINED 19/51 25/50 21/50 29/49 Kidney Tubular Cell: ADENOMA (STANDARD) 0/51 1/50 0/50 2/49 (EXTENDED) 4/51 12/50 1/50 5/49 COMBINED 4/51 13/50 1/50 6/49
Non-Neoplastic Lesions	LIVER: BASOPHILIC FOCUS; CLEAR CELL FOCUS LUNG: MINERALIZATION ADRENAL GLAND: CORTEX; CYTOPLASMIC VACUOLIZATION KIDNEY: MINERALIZATION; INCREASED SEVERITY OF NEPHROPATHY MAMMARY GLAND: LOBULAR HYPERPLASIA TESTES: DEGENERATION; MINERALIZATION
Other Considerations	TESTES: ADENOMA 33/51 20/50 0/50 0/49 MONONUCLEAR CELL LEUKEMIA: 21/51 15/50 7/50 4/50

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Liver: ADENOMA 1/50 1/50 1/50 8/49 COMBINED 1/50 1/50 1/50 10/49 Lung: ADEMONA 0/50 0/50 6/50 1/49 COMBINED 0/50 0/50 7/50 1/49 Skin: COMBINED 0/50 0/50 4/50 5/50
Non-Neoplastic Lesions	LIVER: BASOPHILIC FOCUS; CLEAR CELL FOCUS LUNG: MINERALIZATION ADRENAL GLAND: CORTEX, CYTOPLASMIC VACUOLIZATION KIDNEY: INCREASED SEVERITY OF NEPHROPATHY OVARY: DYSGENESIS, SEVERITY OF DYSGENESIS HEART: MYOCARDIUM; CHRONIC DEGENERATION, SEVERITY OF DEGENERATION
Other Considerations	UTERUS: STROMAL SARCOMA: 5/50 9/50 2/50 0/50 MAMMARY GLAND: FIBROADEMONA 21/50 11/50 1/50 4/50 COMBINED 23/50 11/50 1/50 4/50 PITUITARY GLAND: ADEMONA 27/50 26/50 18/49 14/50 MONONUCLEAR CELL LEUKEMIA: 12/50 11/50 11/50 5/50